1. Kim, SH, Kim, W, Li, XF, et al Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology 2012; 78: 1179–1185.
Google Scholar | Crossref | Medline | ISI2. Wingerchuk, DM, Banwell, B, Bennett, JL, et al International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.
Google Scholar | Crossref | Medline | ISI3. Pittock, SJ, Lucchinetti, CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 2016; 1366: 20–39.
Google Scholar | Crossref | Medline4. Mealy, MA, Kessler, RA, Rimler, Z, et al Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm 2018; 5: e468.
Google Scholar | Crossref | Medline5. Lennon, VA, Kryzer, TJ, Pittock, SJ, et al IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473–477.
Google Scholar | Crossref | Medline | ISI6. Hinson, SR, Romero, MF, Popescu, BF, et al Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012; 109: 1245–1250.
Google Scholar | Crossref | Medline | ISI7. Papadopoulos, MC, Verkman, AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11: 535–544.
Google Scholar | Crossref | Medline | ISI8. Iorio, R, Fryer, JP, Hinson, SR, et al Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun 2013; 40: 21–27.
Google Scholar | Crossref | Medline9. Trebst, C, Jarius, S, Berthele, A, et al Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1–16.
Google Scholar | Crossref | Medline | ISI10. Sherman, E, Han, MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol 2015; 17: 48.
Google Scholar | Crossref | Medline11. Damato, V, Evoli, A, Iorio, R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016; 73: 1342–1348.
Google Scholar | Crossref | Medline | ISI12. Scott, SD . Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract 1998; 6: 195–197.
Google Scholar | Crossref | Medline13. Reff, ME, Carner, K, Chambers, KS, et al Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445.
Google Scholar | Crossref | Medline | ISI14. Cree, BAC, Lamb, S, Morgan, K, et al An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270–1272.
Google Scholar | Crossref | Medline | ISI15. Nikoo, Z, Badihian, S, Shaygannejad, V, et al Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264: 2003–2009.
Google Scholar | Crossref | Medline16. Tahara, M, Oeda, T, Okada, K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19: 298–306.
Google Scholar | Crossref | Medline17. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
Google Scholar | Crossref | Medline | ISI18. Wingerchuk, DM, Lennon, VA, Pittock, SJ, et al Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.
Google Scholar | Crossref | Medline | ISI19. Wingerchuk, DM, Hogancamp, WF, O’Brien, PC, et al The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107–1114.
Google Scholar | Crossref | Medline | ISI20. Boonpheng, B, Thongprayoon, C, Mao, MA, et al Risk of hip fracture in patients on hemodialysis versus peritoneal dialysis: a meta-analysis of observational studies. J Evid Based Med 2019; 12: 98–104.
Google Scholar | Crossref | Medline21. Mokhtari Zanjani, P, Ahmadnia, E, Kharaghani, R. Ectopic pregnancy rate in Iranian midwifery clients and infertile patients treated by assisted reproductive technologies. J Evid Based Med 2019; 12: 56–62.
Google Scholar | Crossref | Medline22. Higgins, J, Thomas, J. Cochrane handbook for systematic reviews of interventions, version 6.2, 2021, https://training.cochrane.org/handbook/current
Google Scholar23. Stang, A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.
Google Scholar | Crossref | Medline | ISI24. Institute TJB . Joanna Briggs Institute reviewers’ manual: 2016 edition. Adelaide, SA, Australia: The Joanna Briggs Institute, 2016.
Google Scholar25. Dent, O . Methodological index for non-randomized studies. ANZ J Surg 2003; 73: 675–676.
Google Scholar | Crossref | Medline26. Wijarnpreecha, K, Panjawatanan, P, Corral, JE, et al Celiac disease and risk of sarcoidosis: a systematic review and meta-analysis. J Evid Based Med 2019; 12: 194–199.
Google Scholar | Crossref | Medline27. Chiengthong, K, Cheungpasitporn, W, Thongprayoon, C, et al Vitamin D deficiency is not associated with graft versus host disease after hematopoietic stem cell transplantation: a meta-analysis. J Evid Based Med 2020; 13: 183–191.
Google Scholar | Crossref | Medline28. Guyatt, GH, Oxman, AD, Vist, GE, et al GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926.
Google Scholar | Crossref | Medline29. Evangelopoulos, ME, Andreadou, E, Koutsis, G, et al Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci 2017; 372: 92–96.
Google Scholar | Crossref | Medline30. Seyed Ahadi, M, Naser Moghadasi, A, Asgari, N, et al Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: a prospective observation in Iranian cases. Caspian J Intern Med 2020; 11: 155–162.
Google Scholar | Medline31. Shaygannejad, V, Fayyazi, E, Badihian, S, et al Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol 2019; 266: 642–650.
Google Scholar | Crossref | Medline32. Torres, J, Pruitt, A, Balcer, L, et al Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351: 31–35.
Google Scholar | Crossref | Medline | ISI33. Liu, H . Efficacy and safety analysis of rituximab in the treatment of optic neuromyelitis optica. Chin J Pract Neurol Disord 2017; 20.
Google Scholar34. Annovazzi, P, Capobianco, M, Moiola, L, et al Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263: 1727–1735.
Google Scholar | Crossref | Medline35. Zhang, C . Clinical efficacy observation of different doses of rituximab for optic neuromyelitis optica spectrum disease. Master’s Thesis, Shanxi Medical University, Taiyuan, China, 2016.
Google Scholar36. Rombouts, MD, Swart, EL, Van den Eertwegh, AJM, et al Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res 2020; 40: 1201–1218.
Google Scholar | Crossref | Medline37. Gao, F, Chai, B, Gu, C, et al Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019; 19: 36.
Google Scholar | Crossref | Medline38. Rituximab prescribing information , http://www.gene.com/download/pdf/rituxan_prescribing.pdf (2014, accessed 12 October 2014).
Google Scholar39. Wong, E . Rituximab in neuromyelitis optica: a review of literature. World J Neurol 2015; 5: 39–46.
Google Scholar | Crossref40. Etemadifar, M, Salari, M, Mirmosayyeb, O, et al Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 2017; 22: 18.
Google Scholar | Crossref | Medline41. Cree, BAC, Bennett, JL, Kim, HJ, et al Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394: 1352–1363.
Google Scholar | Crossref | Medline42. Pierpont, TM, Limper, CB, Richards, KL. Past, present, and future of rituximab – the world’s first oncology monoclonal antibody therapy. Front Oncol 2018; 8: 163.
Google Scholar | Crossref | Medline43. Pittock, SJ, Berthele, A, Fujihara, K, et al Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 614–625.
Google Scholar | Crossref | Medline44. Yamamura, T, Kleiter, I, Fujihara, K, et al Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 2114–2124.
Google Scholar | Crossref | Medline45. Traboulsee, A, Greenberg, BM, Bennett, JL, et al Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19: 402–412.
Google Scholar | Crossref | Medline46. Zhang, C, Zhang, M, Qiu, W, et al Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020; 19: 391–401.
Google Scholar | Crossref | Medline47. Xue, T, Yu, J, Chen, S, et al Different targets of monoclonal antibodies in neuromyelitis optica spectrum disorders: a meta-analysis evidenced from randomized controlled trials. Front Neurol 2020; 11: 604445.
Google Scholar | Crossref | Medline48. Xue, T, Yang, Y, Lu, Q, et al Efficacy and safety of monoclonal antibody therapy in neuromyelitis optica spectrum disorders: evidence from randomized controlled trials. Mult Scler Relat Disord 2020; 43: 102166.
Google Scholar | Crossref | Medline49. Levy, M, Fujihara, K, Palace, J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021; 20: 60–67.
Google Scholar | Crossref | Medline50. Kaegi, C, Wuest, B, Schreiner, J, et al Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 2019; 10: 1990.